Navigation Links
Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
Date:9/10/2009

BATON ROUGE, La., Sept. 10 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide range of cancers including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090421/NE02455LOGO )

"We are pleased to have begun human clinical trials of EP-100 as a novel cancer therapeutic candidate with the potential to offer an improved safety and efficacy profile over existing therapies such as radiation or chemotherapy," said Hector Alila, Ph.D., President of Esperance. "Preclinical studies of EP-100 demonstrated this candidate's efficacy across multiple indications in oncology, including aggressive cancers known to be resistant to the current standards of care and, importantly, studies of EP-100's mechanism-of-action support that it targets and selectively kills cancer cells without harming normal cells."

The Phase 1 study is a multi-center, open-label, dose escalating study designed to evaluate the safety, pharmacodynamic and pharmacokinetic properties of EP-100. This study will enroll adult patients with solid tumors that over-express LHRH receptors as determined by tumor biopsy. Up to a total of 36 patients that are either refractory to the standard of care or for which no standard of care exists may be enrolled in the study. EP-
'/>"/>

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Empowering biomedical researchers with richer, more ... today announced its MR Compatible Small Animal PET ... uses silicon photomultiplier detector technology, so it can ... manufacturers like Bruker and Agilent,” said James Schellenberg, ... enables simultaneous PET and MRI data acquisition with ...
(Date:5/27/2015)... NEW YORK , May 27, 2015  US-Australian drug ... NVGN ), announced today that it will present at the ... New York on May 29, 2015. The venue ... Manhattan . The Brain ... biotechnology companies, the pharmaceutical industry and the investment community to ...
(Date:5/26/2015)... May 26, 2015 Regenestem Network ... stem cells clinic in Buenos Aires, Argentina. The clinic ... critical care specialist. Pastrana has assembled a multidisciplinary team ... orthopedics in her state-of-the-art Puerto Madero office. , ... I to phase IV clinical studies in cellular therapies, ...
(Date:5/26/2015)... , May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: ... Sangamo,s president and CEO, will provide an update on the ... an overview of the company,s business strategy at 1:30pm ET ... Healthcare Conference. The conference is being held in ... be webcast live and may be accessed via a link ...
Breaking Biology Technology:Cubresa Launches Simultaneous PET/MRI Technology 2Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), ... health at home through the merger of rapid diagnostics and health ... Series B Convertible Perpetual Preferred Stock ( IMA-PB). The dividend will ... per share equal to the quotient of (a) $3.00 divided by ...
... , ... that a new market research report is available in ... Perspective , http://www.reportlinker.com/p0164232/Neurostimulation---A-Global-Market-Perspective.html , The ... of aging population, and the resultant rise in age-related ...
... , TUSTIN, Calif., Dec. ... reported completion of patient enrollment in a dose confirmation and ... (GBM), the deadliest form of brain cancer. Cotara is ... as a potential new treatment for GBM. Cotara specifically ...
Cached Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5
(Date:5/21/2015)... , May 21, 2015 ... Imaging Market by Solutions (Hardware, Software, Services), by Applications ... & others), by End-Users (Military & Defense & ... MarketsandMarkets, Thermal Imaging Market is expected to grow ... by 2020, at a Compound Annual Growth Rate ...
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... James Tour, the inventor of the nanocar at Rice ... Prize for experimental nanotechnology for 2008 by the California ... Tour was one of four nominees for the ... nanocars, molecule-sized vehicles with buckyball wheels that served as ...
... (ASM) has been honored with non-profit public relations awards ... initiatives. The awards were announced in Washington, DC, ... series received the award for best podcast. Launched ... increase public understanding and appreciation of the vital role ...
... 2008Once believed to be important only for bone health, ... function in maintaining the immune system throughout life. The ... are clearly documented in a report in the December ... , a peer-reviewed journal published by Mary Ann Liebert, ...
Cached Biology News:Rice's James Tour wins Feynman Prize 2Vitamin D deficiency in infants and nursing mothers carries long-term disease risks 2
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human CXCL14/BRAK Affinity Purified Polyclonal Ab...
mIGSF4A Aff Pur PAb...
Biology Products: